Abstract: The invention relates to transdermal therapeutic systems (TTS) comprising a backing, a reservoir layer containing at least one pharmaceutical active ingredient, and an adhesive. Said transdermal therapeutic systems are characterised in that they are able to continuously adhere to the surface of the skin over a long period of time. During said long period of time, a) there is at least one time interval during which the TTS adhering to the surface of the skin is intensively exposed to water, and b) the active ingredient is transdermally released. The invention also relates to a method for the continuous transdermal release of at least one pharmaceutical active ingredient over a long period of time.

Abstract: A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl.

Abstract: A transdermal patch for the treatment of Alzheimer's disease includes: a backing, a rivastigmine-containing layer, a pressure-sensitive adhesive layer, and a release liner. In the transdermal patch, the rivastigmine-containing layer contains rivastigmine and an alkyl(meth)acrylate resin, the pressure-sensitive adhesive layer is composed of an acrylic pressure-sensitive adhesive containing a (meth)acrylic acid ester having a hydroxyl group, and neither the rivastigmine-containing layer nor the pressure-sensitive adhesive layer contains an anti-oxidizing agent.

Abstract: The present invention provides transdermal therapeutic systems for dispensing a pharmaceutical product, in particular a pharmaceutical product with a low tendency to spontaneously crystallize. The matrix layer or at least one of the matrix layers in said systems contains a silicone hot-melt adhesive, a pharmaceutical product, and particles made of crosslinked polyvinylpyrrolidone. The invention also relates to a method for producing said transdermal therapeutic systems.

Abstract: The present invention provides a transdermal drug delivery system comprising fentanyl or its pharmaceutically acceptable salt and method of making the same.

Abstract: An adhesive preparation comprising a stretchable support and an adhesive layer laminated on at least one side of the support, wherein the stretchable support comprises a interlock woven fabric subjected to crimping processing, the adhesive layer contains 10% by mass or more of methyl salicylate with respect to the total mass of the layer, the whole adhesive preparation has moisture permeability of 1 to 350 g/m2·24 hr measured at a temperature of 40° C. and a relative humidity of 90%, and the methyl salicylate has a plasma AUC0-24 ranging from 3.0 to 60.0 ng·hr/mL in terms of a mean±standard deviation, and salicylic acid as a metabolite of the methyl salicylate has a plasma AUC0-24 ranging from 5000 to 13000 ng·hr/mL in terms of a mean±standard deviation, when the adhesive preparation is applied to a human skin for 8 hours such that an application amount of the adhesive layer applied is 50 to 300 g/m2 and a contact area is 280 cm2.

Abstract: Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer, particularly a hydrophobic pressure-sensitive adhesive (PSA), a plasticizing elastomer, a tackifying resin, and an optional antioxidant. The discontinuous hydrophilic phase, if present, is composed of a crosslinked hydrophilic polymer, particularly a crosslinked cellulosic polymer such as crosslinked sodium carboxymethylcellulose. For those hydrogel compositions containing a continuous hydrophilic phase, the components of the phase include a cellulose ester composition or an acrylate polymer or copolymer, and a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding thereto.

Abstract: The present invention provides a transdermal drug delivery system comprising donepezil or its pharmaceutically acceptable salt and method of making the same.

Abstract: The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a bupreno?hine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid and linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the said pressure-sensitive adhesive, wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact la

Abstract: The present invention is a herbal composition and method of preparing thereof. The herbal composition comprising extracts of Carthami Flos (CF), Dipsaci Radix (DR), Notoginseng Rhizoma (NR) and Rhei Rhizoma (RR). The present invention also relates to an oil-in-water or water-in-oil type nano-emulsion and method of preparing thereof. The nano-emulsion comprises an aqueous phase, an organic phase and a surfactant, wherein said aqueous phase comprises hydrophilic extract of herbal materials and said organic phase comprises hydrophobic extract of said herbal materials. The present invention also relates to a transdermal patch comprises said nano-emulsion. The herbal composition of the present invention is useful in treating traumatic injuries, in particular bone injuries. The present nano-emulsion and patch thereof can promote skin absorption of active ingredients in herb, thereby increasing the herb's bioavailability and efficacy in therapy.

Abstract: According to an embodiment of the present disclosure, a wound dressing system is presented. The wound dressing system includes a fluid permeable support layer, the support layer configured for positioning within a wound and adapted to generally conform to a topography of the wound, and to permit exudates from the wound to pass therethrough. The wound dressing system further includes a plurality of beads supported by the support layer, the beads defining an insulated inter-connected elongate member and an electrode embedded within and extending through at least a portion of the elongate member. Also, a current is generated by an external energy source that electrically flows through the electrode.

Abstract: This invention relates to a transdermal drug delivery device that comprises an active ingredient (AI) layer, having a skin contacting surface and a non-skin contacting surface and comprising a volatile component, a release liner impermeable to the volatile component adjacent the skin contacting surface of the Al layer having a perimeter that extends beyond the perimeter of the Al layer in all directions, and an overlay comprising a pressure sensitive adhesive (PSA) that does not absorb the volatile component adjacent the non-skin contacting surface of the Al layer having a perimeter of which extends beyond the perimeter of the Al layer in all directions, wherein the release liner and the PSA of the overlay are in contact with and adhered to each other around the perimeter of the Al layer to form a seal that reduces or prevents volatile component loss.

Abstract: A device for delivery of a measured or predetermined dose of an active agent to a dermal or mucosal surface comprising: a) a deformable chamber comprising at least one dome-shaped member defining a reservoir for an active agent; and b) a porated disc.

Abstract: According to the invention a transdermal therapeutic system for administering fentanyl or an analogue thereof through the skin is provided that has a pressure-sensitive adhesive matrix layer containing a mixture of two polyisobutylenes with specific storage moduli.

Abstract: The invention relates to a transdermal therapeutic system, comprising a back layer that is impermeable to an active ingredient, a polymer matrix containing the active ingredient, and a protective layer that can be pulled off, wherein 5-aminolevulinic acid hydrochloride is used as the active ingredient and the basic polymer of the polymer matrix is an adhesive polyacrylate. Said transdermal therapeutic system is suitable for diagnosing and treating preliminary stages of skin cancer, such as actinic keratosis, and oncological skin diseases.

Abstract: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, said system being suitable for an application period of at least three days, comprising the layers arranged in the following order with respect to each other: a) a cover layer, b) an active substance layer comprising a polymer matrix containing the active substance, c) an adhesive layer comprising a contact adhesive, which consists of a mixture of one or more polyisobutylenes and one or more polybutenes, and d) a pull-off layer.

Abstract: Disclosed is a transdermal delivery system of multiple adhesive layers having a drug-free adhesive layer as an intermediate layer to control drug delivery rate. The transdermal delivery system enhances transdermal delivery rate in the early stage after application on skin and provides sustained control of the drug delivery rate in the intermediate and later stages. Thus, the drug delivery rate effective for treatment can be controlled in a sustained manner.

Abstract: A reduced pressure treatment apparatus includes a charging chamber storing a first pressure less than an ambient pressure and a regulated chamber storing a second pressure less than the ambient pressure. The first pressure is less than the second pressure. A conduit provides fluid communication between the regulated chamber and the charging chamber. A regulator member is operably associated with the conduit to prevent fluid communication through the conduit when the second pressure is less than or equal to a desired therapy pressure and to allow fluid communication through the conduit when the second pressure exceeds the desired therapy pressure.

Abstract: A vacuum system for draining an open wound from liquids exuded therefrom, comprising an enclosure sealable to the wound circumference, a vacuum pump including a disposable pump unit detachably attachable to a non-disposable drive unit, and a waste container for collection of drained liquids. The enclosure has an outlet connected by means of a tube to an inlet of the pump unit and the waste container is connected to an outlet of the pump unit, such that when the vacuum pump is operated the drained liquids flow through the vacuum pump. The enclosure has one or more bleeding holes provided therethrough or adjacent to its outlet so that ambient air may enter the tube and flow together with the drained liquids. The enclosure and the waste container are disposable so that the drained liquids contact only disposable elements and may be disposed of together with all disposable elements.

Abstract: An adhesive composite dressing useful for applying an active ingredient to a treated skin site, as well as methods of manufacture and use of such dressings. In one embodiment, an adhesive composite dressing comprising an anchor member, a target member, and a folding member, where the anchor member comprises a first skin-contact adhesive, the target member comprises an opening adapted to enable skin treatment, the folding member comprises a drug reservoir, and where the folding member is attached to the anchor portion through a hinge defined by a line of attachment that is not contiguous with an edge of the anchor member.

Abstract: An adhesive patch assembly and method for making same. The assembly can include an adhesive patch and a release liner. The patch can include a backing and a skin-contact adhesive. The release liner can further include a first portion and a second portion separated by a hinge. The first portion can be positioned to overlay the backing of the patch when the release liner is folded upon the hinge, and the second portion can be positioned to underlie the skin-contact adhesive of the patch. The method can include positioning the patch on the release liner, such that patch is located on one of the first portion and the second portion of the release liner; and folding the release liner about to locate the patch between the first portion and the second portion of the release liner.

Abstract: A diaper, diaper sheet insert and/or a diaper wipe sheet with active ingredients integrated therein, including ointments for treating diaper rash, baby oils and lotions for treating dry skin, and/or powder treatments for absorbing moisture, including baby powder, corn starch powders and the like. In a first embodiment, the invention provides a diaper having active ingredients integrated therein comprising a skin-contact surface, at least one inner absorption layer, an outer most layer, and a barrier wall having an active ingredients segment and preventing contact of the active ingredients with the diaper's skin-contact surface. The active ingredient may be applied as a coating or integrated as fine particles within the barrier wall. As diaper is worn, or the active ingredient wipe sheet is wiped on the skin, the skin-contact surface comes into contact with skin, transferring active ingredients onto the skin.

Abstract: A safety syringe system including a safety syringe and an injection site preparation patch adapted for use with the safety syringe. The safety syringe includes a syringe body and a safety shield slidably disposed about the syringe body. The injection site preparation patch has a tissue-facing side and a syringe-facing side, and may include a substrate, a syringe adhesive layer adapted to adhere to a distal flange of the safety shield, a hydrogel layer adapted to adhere to tissue, and removable release liners disposed on either side. The patch may include a medicament, anesthetic, or a thermal compound. Adhesion between the patch and the flange is less than adhesion between the patch and tissue, so that the patch adheres to the shield with sufficient strength to enable the shield to slide over the needle upon withdrawal, but with insufficient strength to cause the patch to pull away from a patient's skin.

Abstract: Transdermal drug delivery systems comprising a drug-containing layer, a backing layer, and an occlusive overlay layer extending beyond the perimeter of the backing layer by 3 to 6 mm in all directions are described. The systems achieve increased drug delivery over an extended time period.

Abstract: Described are transdermal drug delivery compositions comprising amphetamine, methods of making them and therapeutic methods using them. The compositions are provided in a flexible, finite form (e.g. “patch”-type systems) and comprise a polymer matrix that includes amphetamine and an acrylic block copolymer.

Abstract: Described are transdermal drug delivery systems for the transdermal administration of tertiary amine drugs, such as rivastigmine, fentanyl or rotigotine, comprising a polymer matrix comprising a free base form of the drug and at least one carboxyl group-containing compound. In some embodiments, the systems include a rate-controlling membrane and a skin-contacting face adhesive apart from the polymer matrix.

Abstract: Described herein are transdermal compositions comprising methylphenidate in a polymer matrix comprising a non-reactive random acrylic polymer and an acrylic block copolymer. Method of making such compositions, and therapeutic methods using them also are disclosed.

Abstract: Clay composite sheets, mats, films or membranes without polymers. Methods of preparing clay composite sheets, mats, films or membranes without using polymers in the method. Methods of using clay composite sheets, mats, films or membranes prepared without using polymers. Antimicrobial dressing having organo-modified clay product. Transdermal delivery of drugs using organo-modified clay product and methods.

Abstract: An improved band-aid or bandage comprises a dry or dried medicament or medicinal substance in a gauze pad, medical dressing, or pouch. The gauze pad, medical dressing, or pouch is attached to a person's body with an attachment means that has an aperture therethrough, the aperture located adjacent the gauze pad, medical dressing, or pouch. A user can attach the band-aid or bandage to a body and then pass water or another liquid through the aperture to wet the dry or dried medicament or medicinal substance. Once wetted, the medicament or medicinal substance can then suffuse out of the gauze pad, medical dressing, or pouch and onto the part of the body to which it is adjacent, thereby obtaining a desired effect on the body.

Abstract: The present invention provides a transdermal drug delivery system comprising rivastigmine or its pharmaceutically acceptable salt and method of making the same.

Abstract: A therapeutic patch for treating pain capable of compressing a tender area up to a boundary thereof and/or an entire induration with metallic grains or crushed stones by a treatment method in accordance with a classification determined after clarifying a site of pain by pressing a skin with a pressing bar or fingers (first to fourth fingers) to classify the cause of pain, thereby finding the presence of a geographical tender area and/or the presence of an induration on a skin as the cause of pain.

Abstract: Devices for administration of one or more active agents to the skin or mucosa of a host are formed in the nature of a double-disk patch. One outer layer functions as the primary adhesive layer for adhering the patch to the host. The other inner layer contains at least one active agent to be administered to the host. The inner layer is bonded to the outer layer through an opening provided in an interposed active agent impermeable release layer. The release layer separates a circumferential portion of the active agent containing inner layer from the outer adhesive layer to inhibit migration of the active agent therebetween.

Abstract: A transdermal delivery system is provided for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric and/or adhesive coating that is applied to either the transdermal system's backing or release liner. The transdermal delivery device is manufactured to optimize drug loading while providing desirable adhesion to skin or mucosa as well as providing modulation of the drug delivery and profile.

Abstract: Disclosed is a transdermal preparation, comprising sequentially-stacked layers of a backing layer, a barrier layer, a drug adhesive layer and a release layer, wherein the drug adhesive layer contains a drug selected from the group consisting of fentanyl, an analogue thereof and a pharmaceutically-acceptable salt thereof, a skin permeation enhancer of the drug, and a polyacrylate adhesive, which shows a high skin permeation with a low drug dosage, equivalent to one with high drug dosage, by increasing the skin permeation rate of drug.

Abstract: Medical dressings and medical dressing kits that can be used to proved positive pressure wound therapy. The medical dressings include one or more normally-closed valves. The medical dressing kits may further include fittings.

Abstract: The present system and method relates in general to treating warts using a triple combination of therapies contained within a kit. The therapies are easy for a patient to self-apply, eliminating the need for constant physician supervision. The first therapy involves a patient applying a patch within the kit to a wart, which may be in the form of a transdermal patch. The patch may contain a first medicine, such as salicylic acid, and be worn for a period of twelve hours. Once removed, the second therapy involves using an ablative tool to gently slough away the treated wart, said ablative tool being contained within the kit. The third therapy involves applying a second patch, which may contain a second medicine, such as imiquimod, and also be worn for a period of twelve hours. This three step process may be repeated until the wart is fully treated.

Abstract: The present invention pertains generally to the field of transdermal drug delivery. More specifically, the invention relates to a device for the transdermal delivery of an alkaline pharmaceutically active compound that is susceptible to degradation in its free base form (e.g., rivastigmine) that comprises an adhesive matrix layer, a backing layer and a release or protective layer, wherein the adhesive matrix layer comprises said pharmaceutically active compound, triethylcitrate and hydrochloric acid. The invention also relates to methods of preparing such devices.

Abstract: An improved post-operative dressing for providing both breast and, notably, nipple reconstruction and which in particular establishes custom lateral supporting of the nipple annulus. A body is constructed of a medical grade silicone and exhibits a three dimensional shape adapted for placement over the reconstructed breast and an aperture defined by an inner rim configured within the body is adapted to seat therethrough an associated nipple graft or flap in a laterally supporting and non-pressure applied fashion. The dressing may include a controlled release transdermal delivery system for administering at least one medicinal drug directly to the breast mound and/or nipple.

Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.

Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.

Abstract: A drug-containing patch allows transdermal administration of a drug. The patch features a hydrophobic reservoir containing the drug, where the reservoir has a first surface and a second surface. A drug-impermeable backing overlies the first surface of the reservoir. A release sheet may overlie the second surface of the reservoir. The hydrophobic reservoir contains a drug and a hydrophobic matrix, where the hydrophobic matrix includes a hydrophobic filler in an amount which is effective to adsorb said drug; and a mixture of polyisobutylene and mineral oil. The hydrophobic matrix may contain hydrophobic colloidal silica as the hydrophobic filler. The hydrophobic reservoir layer may serve as a skin-contacting adhesive layer. Alternatively, a release-controlling adhesive layer may serve as the skin-contacting adhesive layer. The release-controlling adhesive layer may contain hydrophobic colloidal silica and a mixture of polyisobutylene and mineral oil.

Abstract: Compositions for the transdermal delivery of NSAIDs in a flexible, finite form are described. The compositions comprise a polymer matrix that includes an NSAID and a polymer matrix comprising a blend of silicone and acrylic polymers. A flexible, occlusive backing material also is disclosed.

Abstract: The present invention relates to compositions, devices and methods of delayed and sustained release of energy molecules for brain function to treat nocturnal hypoglycemia. The composition comprises an energy molecule required for human brain function; wherein the release of the energy molecule is delayed and then sustained over a period of time. The device is a transdermal delivery device comprising a reservoir layer containing the composition and a skin permeation enhancer formulation, an adhesive layer, a backing layer and a release liner. The method comprises administering the composition either orally or through the transdermal delivery device to a subject in need thereof immediately prior to going to sleep.

Abstract: The present invention provides a patch preparation that has an extremely low moisture permeability, has a sufficient ODT effect, is excellent in drug releasability and in anchoring property of its drug-containing pressure-sensitive adhesive layer, and has a preferred patch feeling. The patch preparation of the present invention includes a support; and a pressure-sensitive adhesive layer containing an adherent polymer and a drug on one surface of the support, wherein: the support has a polyester base layer, an inorganic oxide layer, and a polyester nonwoven fabric layer in the stated order; the polyester base layer has a thickness of 1.0 ?m to 16 ?m; and the pressure-sensitive adhesive layer is laminated on the polyester nonwoven fabric layer.

Abstract: A film comprising as a film-forming agent an alginate salt of monovalent cation or a mixture of alginate salts containing at least one alginate salt of monovalent cation, the film-forming agent being such that a 10% aqueous solution thereof at a temperature of 20° C. has a viscosity of 100-1000 mPas, as measured at a shear rate of 20 rpm by use of a Brookfield viscometer with a spindle No. 2. A method of preparing the film. The film is useful for delivery of active ingredients to a mammal.

Abstract: A patch for treatment of eyelid diseases that is provided with a support, a pressure-sensitive adhesive layer, and a release layer in this order, wherein (a) the pressure-sensitive adhesive layer includes the following (a-1) to (a-4): (a-1) a styrene-isoprene-styrene block copolymer, a tackifier resin, and a softening agent are contained; (a-2) a ratio (mass ratio) of the styrene-isoprene-styrene block copolymer and the tackifier resin is 1:2 to 1:4; (a-3) a content of the softening agent is 40% to 60% by mass; and (a-4) further 0.005% to 5% by mass of clobetasol or acid ester thereof is contained; and (b) the support has elastic modulus with a Young's modulus of 0.01 to 0.5 GPa: and a method for producing the patch for treatment of eyelid diseases including: forming a pressure-sensitive adhesive layer on a upper surface of a release layer.

Abstract: The invention relates to a transdermal therapeutic system (10) comprising an active ingredient depot (11) that contains at least one active ingredient, comprising an application face which is designed for applying on a skin and which is adhesive on at least some parts of the surface, and comprising a protective film (14) which covers the application face and which comprises a first protective film part (14a) and a second protective film part (14b). The first protective film part (14a) differs from the second protective film part (14b) in terms of physical properties.

Abstract: The invention relates to an antimicrobial barrier device and methods of manufacture. The antimicrobial barrier comprises one or more antimicrobial drugs that inhibit biofilm formation and bacterial and/or fungal growth. The antimicrobial barrier is suited for use with insertable devices (e.g., catheters) to reduce the incidence of infection at and around the insertion site.

Abstract: Therapeutic delivery systems are provided which, in a first embodiment, contain a plurality of multiphase capsules in which first and second therapeutic agents are contained in separate phases within said multiphase capsules, and are disposed to deliver said first and therapeutic agents by at least two different delivery mechanisms.

Abstract: Methods and devices for treatment of damaged tissue are disclosed, including treatment of wounds by employing non-electrically powered, reduced pressure therapy devices with a pressure oscillation mechanism. Maintenance and control of the sub atmospheric pressure exerted may be provided by such devices while minimizing discomfort to the user. The devices may be configured to be worn inconspicuously underneath clothing.